Olmesartán Combix (Olmesartan Medoxomil)

Olmesartan Medoxomil, the active ingredient in Olmesartán Combix, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It is indicated for the treatment of hypertension in adult patients. GNH USA supplies Olmesartán Combix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan Medoxomil acts on the renin‑angiotensin system to lower elevated blood pressure in patients with hypertension.

Hypertension: reduces systolic and diastolic blood pressure, helping to prevent cardiovascular complications.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate head pain. - Fatigue: feeling unusually tired or weak. - Nausea: mild stomach upset. - Abdominal pain: discomfort in the stomach area.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue, or throat that may impair breathing. - Hyperkalemia: elevated potassium levels that can affect heart rhythm. - Acute kidney injury: sudden decline in renal function. - Severe hypotension: marked drop in blood pressure causing faintness.

Olmesartan Medoxomil requires careful monitoring in several clinical situations. - Blood pressure monitoring: ensure adequate control without excessive lowering. - Renal function: assess serum creatinine and eGFR before and during therapy. - Electrolytes: check potassium levels regularly. - Pregnancy: contraindicated in pregnancy (Category D) due to fetal risk. - Concomitant potassium‑sparing agents: avoid to prevent hyperkalemia. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture.

Olmesartan Medoxomil may interact with several medicines.

Major Interactions (Avoid): - Aliskiren in diabetic patients: increased risk of renal impairment and hyperkalemia. - ACE inhibitors or other ARBs: additive effect on potassium and renal function. - Potassium supplements or salt substitutes: risk of hyperkalemia. - NSAIDs (e.g., ibuprofen): may reduce antihypertensive efficacy and impair renal function.

Moderate Interactions (Monitor Closely): - Diuretics (especially thiazides): may enhance hypotensive effect. - Lithium: increased lithium levels, risk of toxicity. - Other antihypertensives: may require dose adjustment. - CYP450 inhibitors (rare): monitor for altered plasma concentrations.